PetMed Express (PETS)
Market Price (12/20/2025): $3.63 | Market Cap: $74.9 MilSector: Consumer Staples | Industry: Drug Retail
PetMed Express (PETS)
Market Price (12/20/2025): $3.63Market Cap: $74.9 MilSector: Consumer StaplesIndustry: Drug Retail
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -72% | Weak multi-year price returns2Y Excs Rtn is -96%, 3Y Excs Rtn is -151% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -0.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.1% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -17%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.2%, Rev Chg QQuarterly Revenue Change % is -22% | |
| Megatrend and thematic driversMegatrends include E-commerce & Digital Retail, Digital Health & Telemedicine, and Health & Wellness Trends. Themes include Direct-to-Consumer Pet Products, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% | |
| High stock price volatilityVol 12M is 101% | ||
| Key risksPETS key risks include [1] significant financial deterioration, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -72% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -33% |
| Megatrend and thematic driversMegatrends include E-commerce & Digital Retail, Digital Health & Telemedicine, and Health & Wellness Trends. Themes include Direct-to-Consumer Pet Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -96%, 3Y Excs Rtn is -151% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -0.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.1% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -17%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.2%, Rev Chg QQuarterly Revenue Change % is -22% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% |
| High stock price volatilityVol 12M is 101% |
| Key risksPETS key risks include [1] significant financial deterioration, Show more. |
Valuation, Metrics & Events
PETS Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are the key points explaining the stock movement for PetMed Express (PETS) from August 31, 2025, to December 20, 2025:
1. Multiple unsolicited acquisition proposals generated investor interest.
On December 16, 2025, Cardone Ventures announced an unsolicited all-cash proposal to acquire PetMed Express for $4.25 per share, valuing the company at approximately $89 million. This followed an earlier unsolicited and non-binding acquisition proposal from SilverCape Investments Limited commented on by PetMed Express on December 11, 2025. Such proposals typically create upward pressure on a stock's price.
2. A significant stock price surge was observed on December 11, 2025, driven by company actions and investor optimism.
PetMed Express Inc. stock trended up by 67.8% on December 11, 2025. This surge was attributed to investor optimism, the introduction of a new Holiday Collection focused on pet wellness, and the extension of PetMeds' shareholder rights plan until December 2, 2026, which was seen as a protective measure indicating the Board's belief that the stock price undervalued the company.
Show more
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PETS Return | 41% | -18% | -26% | -55% | -36% | -24% | -81% |
| Peers Return | 137% | 2% | -43% | 12% | 28% | -5% | 90% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| PETS Win Rate | 58% | 33% | 42% | 33% | 42% | 25% | |
| Peers Win Rate | 73% | 50% | 38% | 48% | 43% | 42% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| PETS Max Drawdown | -5% | -18% | -28% | -59% | -61% | -67% | |
| Peers Max Drawdown | -27% | -25% | -54% | -25% | -24% | -29% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: CHWY, IDXX, CENT, FRPT, TRUP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/19/2025 (YTD)
How Low Can It Go
| Event | PETS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -86.7% | -25.4% |
| % Gain to Breakeven | 651.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -30.7% | -33.9% |
| % Gain to Breakeven | 44.2% | 51.3% |
| Time to Breakeven | 141 days | 148 days |
| 2018 Correction | ||
| % Loss | -71.8% | -19.8% |
| % Gain to Breakeven | 254.7% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -30.7% | -56.8% |
| % Gain to Breakeven | 44.4% | 131.3% |
| Time to Breakeven | 243 days | 1,480 days |
Compare to HITI, WGRX, PETS, SCNX
In The Past
PetMed Express's stock fell -86.7% during the 2022 Inflation Shock from a high on 1/27/2021. A -86.7% loss requires a 651.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| PetMed Express Earnings Notes | ||
| Would You Still Hold PetMed Express Stock If It Fell 30%? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select past ideas related to PETS. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BF-B | Brown-Forman | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -0.9% | -0.9% | -0.9% |
| 11302025 | CPB | Campbell's | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -6.2% | -6.2% | -7.5% |
| 11212025 | ENR | Energizer | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.3% | 10.3% | -5.3% |
| 11212025 | FLO | Flowers Foods | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 5.8% | 5.8% | -1.6% |
| 11142025 | CLX | Clorox | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -5.2% | -5.2% | -5.2% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BF-B | Brown-Forman | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -0.9% | -0.9% | -0.9% |
| 11302025 | CPB | Campbell's | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -6.2% | -6.2% | -7.5% |
| 11212025 | ENR | Energizer | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.3% | 10.3% | -5.3% |
| 11212025 | FLO | Flowers Foods | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 5.8% | 5.8% | -1.6% |
| 11142025 | CLX | Clorox | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -5.2% | -5.2% | -5.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for PetMed Express
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 35.23 |
| Mkt Cap | 2.5 |
| Rev LTM | 2,264 |
| Op Inc LTM | 148 |
| FCF LTM | 181 |
| FCF 3Y Avg | 176 |
| CFO LTM | 244 |
| CFO 3Y Avg | 243 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.2% |
| Rev Chg 3Y Avg | 8.1% |
| Rev Chg Q | 10.2% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Mgn LTM | 5.7% |
| Op Mgn 3Y Avg | 2.9% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 8.3% |
| CFO/Rev 3Y Avg | 8.2% |
| FCF/Rev LTM | 4.5% |
| FCF/Rev 3Y Avg | 3.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.5 |
| P/S | 1.1 |
| P/EBIT | 46.8 |
| P/E | 39.7 |
| P/CFO | 19.6 |
| Total Yield | 1.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.6% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.2% |
| 3M Rtn | -0.7% |
| 6M Rtn | -11.3% |
| 12M Rtn | -22.1% |
| 3Y Rtn | -5.5% |
| 1M Excs Rtn | 2.3% |
| 3M Excs Rtn | -0.6% |
| 6M Excs Rtn | -24.2% |
| 12M Excs Rtn | -40.5% |
| 3Y Excs Rtn | -80.3% |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/14/2025 | 0.4% | 3.5% | 13.3% |
| 2/10/2025 | -14.0% | -15.0% | -22.0% |
| 11/6/2024 | 35.8% | 25.0% | 36.3% |
| 6/11/2024 | -11.5% | -8.3% | -16.8% |
| 2/8/2024 | 1.9% | -9.4% | -12.4% |
| 10/30/2023 | -24.9% | -22.7% | -21.1% |
| 7/31/2023 | -5.9% | -8.9% | -21.4% |
| 5/22/2023 | 3.4% | -3.8% | -8.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 6 | 8 |
| # Negative | 9 | 14 | 12 |
| Median Positive | 2.0% | 4.6% | 8.0% |
| Median Negative | -6.6% | -5.7% | -11.2% |
| Max Positive | 35.8% | 74.0% | 36.3% |
| Max Negative | -24.9% | -22.7% | -22.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 3312025 | 10142025 | 10-K 3/31/2025 |
| 12312024 | 2102025 | 10-Q 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8072024 | 10-Q 6/30/2024 |
| 3312024 | 6142024 | 10-K 3/31/2024 |
| 12312023 | 4152024 | 10-Q 12/31/2023 |
| 9302023 | 10312023 | 10-Q 9/30/2023 |
| 6302023 | 8022023 | 10-Q 6/30/2023 |
| 3312023 | 5232023 | 10-K 3/31/2023 |
| 12312022 | 2072023 | 10-Q 12/31/2022 |
| 9302022 | 11082022 | 10-Q 9/30/2022 |
| 6302022 | 8022022 | 10-Q 6/30/2022 |
| 3312022 | 5242022 | 10-K 3/31/2022 |
| 12312021 | 2042022 | 10-Q 12/31/2021 |
| 9302021 | 11022021 | 10-Q 9/30/2021 |
| 6302021 | 7302021 | 10-Q 6/30/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |